What is the role of certolizumab in the treatment of ankylosing spondylitis (AS) and undifferentiated spondyloarthropathy (USpA)?

Updated: Feb 02, 2021
  • Author: Lawrence H Brent, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

In 2019, the US Food and Drug Administration (FDA) approved certolizumab for treatment of nonradiographic axial spondyloarthritis (nr-axSpA) with objective inflammation. Certolizumab is the first therapy approved for nr-axSpA. Approval was based on data from the phase 3 C-AXSPAND study, which favored certolizumab over placebo at both week 12 and week 52. At week 52, major improvement in the Ankylosing Spondylitis Disease Activity Score (ASDAS) had occurred in 42% of patients receiving certolizumab, compared with 7% of those receiving placebo. [104] IL-17i, secukinumab and ixekizumab, are also FDA approved for the treatment of nr-axSpA. [105, 106] Other TNFi and IL-17i have had similar results in patients with nr-axSpA.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!